Rhythm Pharma Outlines Robust Start To Newly Approved Drug For Genetic Condition
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) announced that over 35 physicians have written 50+ prescriptions for Imcivree (setmelanotide) for Bardet-Biedl syndrome…
Vaxxinity’s Vaccine Candidate Shows Durable Cholesterol Lowering Activity In Animal Models
Vaxxinity Inc (NASDAQ:VAXX) announced data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in non-human primates. The company also selected VXX-401…
Detailed Data From Phase II Crenezumab Alzheimer’s Prevention Initiative Study In Autosomal Dominant Alzheimer’s Disease Presented At AAIC; Says Crenezumab Was Safe And Well Tolerated With No Cases Of ARIA-E Observed During The Up To Eight-Year Study
Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year study
As previously reported, numerical differences favoring crenezumab over placebo were confirmed across the
Acurx Announces New Data Presentations From Ongoing Ph2 Clinical Trial Program Of Ibezapolstat For CDI At 16th Biennial Congress Of Anaerobe Society of America
New data link beneficial microbiome changes in Ph2a CDI patients to earlier results from Ph1 healthy volunteers to predict potential anti-recurrence properties of ibezapolstat
New in vitro data show ibezapolstat is
Applied DNA Initiates Analytical Validation Of PCR-based Diagnostic Test Specific To Monkeypox Virus
Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in polymerase chain reaction ("PCR")-based technologies, announced that its wholly-owned clinical laboratory subsidiary, Applied
AbbVie, Sosei Build In 2020 Pact With New Neurological Disease-Focused Agreement
Sosei Group Corporation and AbbVie Inc (NYSE:ABBV) announced a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules…
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application…
Aerie Shares Gain Following Patient Dosing In Late-Stage Dry Eye Disease Study
Aerie Pharmaceuticals (NASDAQ: AERI) has initiated patient dosing in the Phase 3 registrational COMET-3 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).
‘Novel Approach For Retinal Disease Needs’ Stock Belite Bio Has 70% Potential Upside According To This Analyst
HC Wainwright initiated coverage on Belite Bio Inc (NASDAQ:BLTE) with a Buy rating and price target of $58 per ADS. Belite Bio…
Stealth BioTherapeutics Enters Going Private Agreement
Stealth BioTherapeutics Corp (NASDAQ:MITO) will be acquired by a consortium of investors led by Morningside Venture (I) Investments Ltd and J.…